Posted by Michael Wonder on 18 Jul 2024
Zilbrysq (zilucoplan injection) now approved for adults with generalised myasthenia gravis in Canada
17 July 2024 - Health Canada's approval is supported by the pivotal Phase 3 RAISE study in generalised myasthenia gravis in adult patients which demonstrated that treatment with Zilbrysq resulted in statistically significant and clinically meaningful improvements in gMG-specific efficacy outcomes.
UCB Canada is pleased to announce that Zinbrysq (zilucoplan injection) received authorisation from Health Canada on 11 July 2024 for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
